CymaBay Therapeutics Inc. (CBAY)

NASDAQ: CBAY · IEX Real-Time Price · USD
3.95
+0.01 (0.25%)
At close: Dec 9, 2022 4:00 PM
4.00
+0.05 (1.27%)
After-hours: Dec 9, 2022 6:11 PM EST
0.25%
Market Cap 333.64M
Revenue (ttm) n/a
Net Income (ttm) -105.91M
Shares Out 87.80M
EPS (ttm) -1.32
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 659,091
Open 3.9
Previous Close 3.94
Day's Range 3.87 - 4.02
52-Week Range 1.67 - 4.3
Beta 0.53
Analysts Buy
Price Target 10.20 (+158.2%)
Earnings Date Nov 14, 2022

About CBAY

CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta that is in phase III clinical study for the treatments of primary biliary cholangitis (PBC), as well as has completed Phase 2b clinical study to treat patients with nonalcoholic steatohepatitis. The company also develops MBX-2982, which is in Phase 2a clinical stu... [Read more]

Industry Pharmaceuticals
CEO Sujal Shah
Employees 59
Stock Exchange NASDAQ
Ticker Symbol CBAY
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 15 analysts, the average rating for CBAY stock is "Buy." The 12-month stock price forecast is 10.2, which is an increase of 158.23% from the latest price.

Price Target
$10.2
(158.23% upside)
Analyst Consensus: Buy
Stock Forecasts

News

CymaBay Reports Third Quarter and Nine Months Ended September 30, 2022 Financial Results and Provides Corporate Update

Conference call and webcast today at 4:30 p.m. ET Conference call and webcast today at 4:30 p.m. ET

3 weeks ago - GlobeNewsWire

CymaBay Therapeutics to Report Third Quarter of 2022 Financial Results on Monday, November 14, 2022

NEWARK, Calif., Nov. 07, 2022 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseas...

1 month ago - GlobeNewsWire

CymaBay Therapeutics Presents Additional Analyses from Clinical Studies of Seladelpar for Patients with Primary Bilia...

NEWARK, Calif., Nov. 04, 2022 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused on developing and providing access to innovative therapies for patients w...

1 month ago - GlobeNewsWire

CymaBay Therapeutics to Present at Upcoming Investment Conferences

NEWARK, Calif., Nov. 03, 2022 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseas...

1 month ago - GlobeNewsWire

CymaBay Announces Appointment of Charles McWherter, Ph.D. to Chief Scientific Officer and President of Research and D...

NEWARK, Calif., Nov. 01, 2022 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseas...

1 month ago - GlobeNewsWire

CymaBay Therapeutics Announces Three Presentations at The Liver Meeting® 2022

NEWARK, Calif., Oct. 03, 2022 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused on developing and providing access to innovative therapies for patients w...

2 months ago - GlobeNewsWire

CymaBay Therapeutics Hosting Virtual Analyst Day on September 22

Redefining Expectations for PBC Patients

2 months ago - GlobeNewsWire

CymaBay Therapeutics to Present at the H.C. Wainwright 24th Annual Global Investment Conference

NEWARK, Calif., Sept. 06, 2022 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic disea...

3 months ago - GlobeNewsWire

CymaBay Therapeutics Inc. (CBAY) Upgraded to Buy: What Does It Mean for the Stock?

CymaBay Therapeutics Inc. (CBAY) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

3 months ago - Zacks Investment Research

CymaBay Therapeutics to Participate in B. Riley's Mini PBC Symposium on August 24, 2022

NEWARK, Calif., Aug. 24, 2022 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseas...

3 months ago - GlobeNewsWire

CymaBay Therapeutics Inc. (CBAY) Just Flashed Golden Cross Signal: Do You Buy?

Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?

3 months ago - Zacks Investment Research

CymaBay Reports Second Quarter and Six Months Ended June 30, 2022 Financial Results and Provides Corporate Update

Enrollment completed in RESPONSE with 193 patients enrolled in over 20 countries

3 months ago - GlobeNewsWire

CymaBay Therapeutics to Report Second Quarter of 2022 Financial Results on Thursday, August 11, 2022

NEWARK, Calif., Aug. 04, 2022 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseas...

4 months ago - GlobeNewsWire

CymaBay Completes Enrollment for the RESPONSE Global Phase 3 Study Evaluating Seladelpar for Patients with Primary Bi...

NEWARK, Calif., Aug. 01, 2022 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseas...

4 months ago - GlobeNewsWire

CymaBay Therapeutics Presents Positive PBC Data at the International Liver Congress™ 2022

NEWARK, Calif., June 22, 2022 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseas...

5 months ago - GlobeNewsWire

CymaBay Therapeutics Announces Presentations During The International Liver Congress™ 2022

NEWARK, Calif., June 08, 2022 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseas...

6 months ago - GlobeNewsWire

CymaBay Therapeutics Presents New Findings that Seladelpar Treatment of PBC Patients for Two Years Predicts Improved ...

NEWARK, Calif., May 23, 2022 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused on developing and providing access to innovative therapies for patients wi...

6 months ago - GlobeNewsWire

CymaBay Reports First Quarter 2022 Financial Results and Provides Corporate Update

Over 150 clinical sites now activated in RESPONSE Phase 3 clinical trial

6 months ago - GlobeNewsWire

CymaBay Therapeutics Announces Presentations at Digestive Disease Week® 2022

Seladelpar Phase 2 Study Selected for DDW Presidential Plenary Session Seladelpar Phase 2 Study Selected for DDW Presidential Plenary Session

6 months ago - GlobeNewsWire

CymaBay Therapeutics to Report First Quarter of 2022 Financial Results on Thursday, May 12, 2022

NEWARK, Calif., May 05, 2022 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic disease...

7 months ago - GlobeNewsWire

CymaBay Therapeutics Announces Publication of Results From a 52-Week, Open-Label, Phase 2 Study of Seladelpar in Pati...

NEWARK, Calif., April 04, 2022 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused on developing and providing access to innovative therapies for patients ...

8 months ago - GlobeNewsWire

CymaBay Announces Appointment of Éric Lefebvre, M.D. to Board of Directors

NEWARK, Calif., March 17, 2022 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic disea...

8 months ago - GlobeNewsWire

CymaBay Reports Fourth Quarter and Year Ended December 31, 2021 Financial Results and Provides Corporate Update

Conference call and webcast today at 4:30 p.m. ET Conference call and webcast today at 4:30 p.m. ET

8 months ago - GlobeNewsWire

CymaBay Therapeutics to Report Fourth Quarter and Full Year 2021 Financial Results on Thursday, March 17, 2022

NEWARK, Calif., March 10, 2022 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic disea...

8 months ago - GlobeNewsWire

CymaBay Therapeutics to Present at Upcoming Investor Conferences

NEWARK, Calif., Feb. 10, 2022 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseas...

9 months ago - GlobeNewsWire